Inspra

(eplerenone)

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Eplerenone is used to treat high blood pressure and to improve survival in patients who have had a heart attack. It helps the body retain less salt and water, which reduces strain on the heart and blood vessels.[2] Inspra is currently approved and in use across 32 indications[4].[1]

Inspra is one of 571 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

570

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Left Ventricular HypertrophyActive, not recruiting

Ischemia Reperfusion InjuryActive, not recruiting

StrokeActive, not recruiting

CardiomyopathyCompleted

RetinopathyUnknown status

Diabetic NephropathyApproved

Abdominal Aortic AneurysmUnknown status

Primary AldosteronismRecruiting

HIV InfectionPreclinical

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Left Ventricular HypertrophyApproved

Active, not recruiting

Ischemia Reperfusion InjuryPreclinical

Active, not recruiting

StrokeApproved

Active, not recruiting

CardiomyopathyApproved

Completed

RetinopathyApproved

Unknown status

Diabetic NephropathyApproved

Approved

Abdominal Aortic AneurysmApproved

Unknown status

Primary AldosteronismApproved

Recruiting

Showing 10 of 32 indications

Competition

Competitive Landscape

198 competitors in Heart Failure

#DrugCompanyPhaseTrials

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Activase

Zemplar

Adriamycin

Savaysa

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Intraocular Pressure

NCT07795762

Post-ApprovalNot yet recruiting

Atrial Fibrillation

NCT06168994

Q4 2027

Phase 2Recruiting

Renal Failure

NCT07029503

Phase 1Recruiting

Preeclampsia

NCT06749418

Post-ApprovalRecruiting

Hypertension

NCT05593055

Q1 2028

ApprovedRecruiting

Primary Aldosteronism

NCT05030545

Clinical

Trials by Indication[1]

Hypertension11 trials

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00817635·155 enrolled

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Recruiting·—·Phase 4·NCT05593055·75 enrolled

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT01996449·14 enrolled

Show 8 more trials

Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?

Unknown status·SShaare Zedek Medical Center·Phase 4·NCT00553722·27 enrolled

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00147589·320 enrolled

Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT00138944·85 enrolled

A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00649311·248 enrolled

Treatment of Supine Hypertension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223717·152 enrolled

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00147615·140 enrolled

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of Pregnancy

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07238400·90 enrolled

Role of LSD1 in Hypertension in Blacks

Completed·BBrigham and Women's Hospital·Approved·NCT04840342·300 enrolled

Heart Failure5 trials

Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.··NCT03342690·1,165 enrolled

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01115855·221 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Show 2 more trials

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00232180·2,743 enrolled

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00082589·250 enrolled

Retinopathy5 trials

Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy

Unknown status·LLeiden University Medical Center·Phase 4·NCT03079141·107 enrolled

A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy

Unknown status·PPrim. Prof. Dr. Oliver Findl, MBA·Phase 2/3·NCT02215330·60 enrolled

Eplerenone for Central Serous Chorioretinopathy

Completed·TTufts Medical Center·Phase 2·NCT01822561·17 enrolled

Show 2 more trials

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Completed·WWills Eye·N/A·NCT01990677·108 enrolled

Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT02153125·30 enrolled

Tics4 trials

Pharmacokinetics Study of Eplerenone Coated Tablets

Withdrawn·BBiolab Sanus Farmaceutica·Phase 1·NCT02957435

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01237899·32 enrolled

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

Completed· Bayer logo

Bayer·Phase 1·NCT01473108·67 enrolled

Show 1 more trial

Pharmacokinetics of Eplerenone Tablet

Withdrawn·BBiolab Sanus Farmaceutica·Phase 1·NCT02607657

Chronic Kidney Disease4 trials

Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function

Terminated·LLene Boesby·Phase 3·NCT01100203·54 enrolled

A Study of LY2623091 in Male and Females With Chronic Kidney Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01427972·42 enrolled

Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients

Withdrawn·JJichi Medical University·Phase 4·NCT01302236

Show 1 more trial

The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)

Unknown status·MMedical University of Vienna·N/A·NCT01832558·24 enrolled

51 more indications

Essential Hypertension4 trials

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Terminated· Novartis logo

Novartis·Phase 2·NCT01373086·19 enrolled

Study of CS-3150 in Patients With Essential Hypertension

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02890173·1,001 enrolled

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Terminated·—·N/A·NCT00980031·20 enrolled

Show 1 more trial

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00758524·628 enrolled

Diastolic Heart Failure3 trials

The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure

Completed·SSt Vincent's University Hospital, Ireland·N/A·NCT00505336·43 enrolled

Aldosterone Antagonism in Diastolic Heart Failure

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108251·48 enrolled

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

Terminated·TThe Cleveland Clinic·Phase 4·NCT00293150·11 enrolled

Primary Aldosteronism3 trials

Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.

Unknown status·EErasmus Medical Center··NCT00407784·500 enrolled

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Recruiting·BBrigham and Women's Hospital·Approved·NCT05030545·40 enrolled

Early Aldosterone Blockade to Prevent Hypertension and Cardiorenal Damage in Subclinical Primary Aldosteronism

Not yet recruiting·XXinjiang Medical University·Preclinical·NCT07727252·880 enrolled

Atrial Fibrillation2 trials

EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

Terminated·UUniversity Hospital, Saarland·Phase 2·NCT00647192·38 enrolled

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease

Not yet recruiting·—·Phase 4·NCT06168994·100 enrolled

Cardiomyopathy2 trials

PHOspholamban RElated CArdiomyopathy STudy - Intervention

Completed·MM.p. van den Berg, MD, PhD, professor in Cardiology·Phase 3·NCT01857856·84 enrolled

CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone

Completed·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 4·NCT00401856·42 enrolled

Duchenne Muscular Dystrophy2 trials

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Completed·OOhio State University·Phase 3·NCT02354352·52 enrolled

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

Completed·SSubha Raman·N/A·NCT01521546·42 enrolled

Type 2 Diabetes2 trials

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

Completed·HHerlev Hospital·Phase 4·NCT02809963·140 enrolled

The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes

Completed·UUniversity of Southern Denmark·N/A·NCT03017703·27 enrolled

Blood Pressure2 trials

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

Terminated·UUniversity of Mississippi Medical Center·N/A·NCT00825188·10 enrolled

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

Unknown status·HHippocration General Hospital·N/A·NCT06208072·50 enrolled

Metabolic Syndrome2 trials

Effect of Eplerenone on Endothelial Function in Metabolic Syndrome

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT01319344·42 enrolled

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

Completed·BBrigham and Women's Hospital·Approved·NCT04519164·79 enrolled

Preeclampsia2 trials

Vascular Effects of High-Salt After Preeclampsia

Recruiting·—·Phase 1·NCT06749418·40 enrolled

Contribution of Mineralocorticoid Receptor Signaling to Vascular Dysfunction & Aberrant Inflammation After Preeclampsia

Withdrawn·AAnna Stanhewicz, PhD·Phase 1·NCT07345845

Kidney Disease1 trial

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03165240·62 enrolled

Cardiovascular Disease1 trial

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

Completed·MMassachusetts General Hospital·N/A·NCT02740179·40 enrolled

Hemodialysis1 trial

Eplerenone in Hemodialysis Trial

Completed·MMcMaster University·N/A·NCT01650012·158 enrolled

Inflammatory Response1 trial

Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults

Completed·—·N/A·NCT01786551·16 enrolled

Effectiveness1 trial

Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Completed· Pfizer logo

Pfizer·Phase 4·NCT00147563·34 enrolled

Obesity1 trial

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Terminated·VVanderbilt University·Phase 4·NCT00608465·4 enrolled

MPA1 trial

Eplerenone Versus PDT: Comparative Study by OCTA

Completed·FFederico II University··NCT05104138·30 enrolled

Myocardial Ischemia1 trial

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

Completed·UUniversity of Florida·Phase 4·NCT00187889·70 enrolled

Efficacy and Safety1 trial

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT02345044·426 enrolled

Congenital Heart Disease1 trial

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

Terminated·WWashington University School of Medicine·Phase 4·NCT01971593·26 enrolled

Systemic Right Ventricle1 trial

Eplerenone in Systemic Right Ventricle

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00703352·26 enrolled

Diabetes Mellitus1 trial

Aldosterone and Vascular Disease in Diabetes Mellitus

Completed·—·N/A·NCT00214825·46 enrolled

Left Ventricular Hypertrophy1 trial

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

Unknown status·NNagoya University·Phase 4·NCT01893788·100 enrolled

Chronic Renal Disease1 trial

Inhibition of Aldosterone in Patients With Chronic Renal Disease

Completed·LLene Boesby·Phase 4·NCT00430924·42 enrolled

Microvascular Function1 trial

Aldosterone Antagonism and Microvascular Function

Terminated·MMaastricht University Medical Center·Phase 4·NCT01887119·25 enrolled

Outcome1 trial

Pressure Assessment to Improve Outcomes After TAVR: a Registry

Completed·NNorth Florida Foundation for Research and Education·Phase 1·NCT03923530·12 enrolled

ALD1 trial

The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production

Completed·—·Phase 1·NCT02871648·23 enrolled

Breast Cancer1 trial

Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

Terminated·UUniversity of British Columbia·Phase 2/3·NCT01708798·44 enrolled

Systolic Heart Failure1 trial

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

Enrolling by invitation·—·Phase 4·NCT03984591·7,200 enrolled

Hypertrophy1 trial

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

Withdrawn·WWashington University School of Medicine·Phase 4·NCT01275352

Ischemia Reperfusion Injury1 trial

The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium

Completed·RRadboud University Medical Center·N/A·NCT02118753·24 enrolled

Renal Transplant1 trial

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

Active, not recruiting·—·Phase 3·NCT02490904·132 enrolled

Albuminuria1 trial

Eplerenone, ACE Inhibition and Albuminuria

Completed·RRadboud University Medical Center·Phase 2·NCT00315016·30 enrolled

Type 2 Diabetes Mellitus1 trial

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone

Completed· Bayer logo

Bayer·Phase 2·NCT01955694·72 enrolled

Treatment1 trial

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Terminated·WWagner Macula & Retina Center·Phase 2·NCT04300881·2 enrolled

Biomarkers1 trial

Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)

Withdrawn·UUniversity of Michigan·Phase 4·NCT04746495

Single Dose1 trial

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02532998·40 enrolled

Renal Failure1 trial

Swedish Cardiac And Renal Failure Study-1

Recruiting·KKarolinska Institutet·Phase 2·NCT07029503·40 enrolled

Primary Hyperparathyroidism1 trial

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Completed·—·Phase 2/3·NCT02525796·69 enrolled

Myocardial Infarction1 trial

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT01176968·1,012 enrolled

Abdominal Aortic Aneurysm1 trial

Eplerenone in the Management of Abdominal Aortic Aneurysms

Unknown status·BBayside Health·Phase 4·NCT02345590·172 enrolled

Glucose intolerance1 trial

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

Completed·MMontreal Heart Institute·Phase 3·NCT01586442·62 enrolled

TED1 trial

EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety

Unknown status·CCHU de Reims·Phase 2·NCT01834768·31 enrolled

Cirrhosis1 trial

Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects

Withdrawn·EEmma Nilsson·Phase 2·NCT01801228

Hypoglycemia1 trial

Hypoglycemia and the Mineralocorticoid Receptor

Completed·—·N/A·NCT01394627·21 enrolled

Diabetes1 trial

Detection of Diffuse Scar in Patients With Diabetes

Withdrawn·—·Phase 4·NCT01794091

Heart Attack1 trial

Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack

Completed·NNHS Greater Glasgow and Clyde·Phase 4·NCT00132093·100 enrolled

HIV (Human Immunodeficiency Virus)1 trial

Study to Understand the Reduction in Arterial Inflammation Combining Statins and Eplerenone

Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT07892664·124 enrolled

Kidney1 trial

Randomized Controlled Trial Evaluating the Impact of Mineralocorticoid Receptor Blockade by Eplerenone on Echocardiographic Abnormalities Among Kidney Graft Recipient Under Calcineurin Inhibitors. KT-CANOPY: Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.

Not yet recruiting·CCentral Hospital, Nancy, France·Phase 3·NCT07828223·132 enrolled

Intraocular Pressure1 trial

Effect of Short-Term Oral Eplerenone on Intraocular Pressure in Healthy Adult Volunteers: A Randomized, Double-Masked, Placebo-Controlled Crossover Study

Not yet recruiting·UUniversity of Florida·Phase 1·NCT07795762·30 enrolled

Unspecified3 trials

Eplerenone and Extracellular Adenosine Formation

Completed·RRadboud University Medical Center·Phase 4·NCT01837108·14 enrolled

Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

Completed·SSanthera Pharmaceuticals·Phase 1·NCT06649409·30 enrolled

Diurnal Variation of Plasminogen Activator Inhibitor-1

Completed·VVanderbilt University Medical Center·Phase 4·NCT00515021·21 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 27, 2002

INSPRA

NDA NDA021437

Sep 27, 2002

INSPRA

NDA NDA021437

Oct 7, 2003

INSPRA

NDA NDA021437

Jan 31, 2008

INSPRA

NDA NDA021437

May 7, 2008

INSPRA

NDA NDA021437

Jun 22, 2012

INSPRA

NDA NDA021437

Apr 15, 2013

INSPRA

NDA NDA021437

May 16, 2013

INSPRA

NDA NDA021437

Jul 26, 2013

INSPRA

NDA NDA021437

May 4, 2016

INSPRA

NDA NDA021437

May 30, 2018

INSPRA

NDA NDA021437

Jun 16, 2025

INSPRA

NDA NDA021437

Sources

References

[1]
ClinicalTrials.gov — 96 trial records for eplerenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Inspra drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — eplerenone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for eplerenone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021437). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Mineralocorticoid Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Inspra

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Hypertension11 trials

Heart Failure5 trials

Retinopathy5 trials

Tics4 trials

Chronic Kidney Disease4 trials

Essential Hypertension4 trials

Diastolic Heart Failure3 trials

Primary Aldosteronism3 trials

Atrial Fibrillation2 trials

Cardiomyopathy2 trials

Duchenne Muscular Dystrophy2 trials

Type 2 Diabetes2 trials

Blood Pressure2 trials

Metabolic Syndrome2 trials

Preeclampsia2 trials

Kidney Disease1 trial

Cardiovascular Disease1 trial

Hemodialysis1 trial

Inflammatory Response1 trial

Effectiveness1 trial

Obesity1 trial

MPA1 trial

Myocardial Ischemia1 trial

Efficacy and Safety1 trial

Congenital Heart Disease1 trial

Systemic Right Ventricle1 trial

Diabetes Mellitus1 trial

Left Ventricular Hypertrophy1 trial

Chronic Renal Disease1 trial

Microvascular Function1 trial

Outcome1 trial

ALD1 trial

Breast Cancer1 trial

Systolic Heart Failure1 trial

Hypertrophy1 trial

Ischemia Reperfusion Injury1 trial

Renal Transplant1 trial

Albuminuria1 trial

Type 2 Diabetes Mellitus1 trial

Treatment1 trial

Biomarkers1 trial

Single Dose1 trial

Renal Failure1 trial

Primary Hyperparathyroidism1 trial

Myocardial Infarction1 trial

Abdominal Aortic Aneurysm1 trial

Glucose intolerance1 trial

TED1 trial

Cirrhosis1 trial

Hypoglycemia1 trial

Diabetes1 trial

Heart Attack1 trial

HIV (Human Immunodeficiency Virus)1 trial

Kidney1 trial

Intraocular Pressure1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News